Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px
Collaboration › Details

Black Diamond Therapeutics–JPMorgan Chase: investor conference, 202301 supply service BDTX presents at JP Morgan Healthcare Conference 2023


Period Period 2023-01-12
Region Region San Francisco, CA
  Country United States (USA)
Organisations Partner, 1st Black Diamond Therapeutics Inc. (Nasdaq: BDTX)
  Group Black Diamond Therapeutics (Group)
  Partner, 2nd J.P. Morgan Securities LLC
  Group JPMorgan Chase (Group)
Products Product J.P. Morgan 41st Annual Healthcare Conference 2023 San Francisco
  Product 2 personalised medicine / precision medicine
Persons Person Epstein, David M. (Black Diamond Therapeutics 2017– CEO + Co-Founder)
  Person 2 Seidel, Julie (Precision Medicine Group 202003 Managing Director at Stern IR)

Black Diamond Therapeutics, Inc.. (1/5/23). "Press Release: Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference". Cambridge, MA & New York, NY.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update on the Company’s progress at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 9:00 a.m. PT in San Francisco, California.

A live webcast of the presentation can be accessed by visiting the investors relations section of the Company’s website at: A replay of the webcast will also be available and archived for 90 days following the event.

About Black Diamond

Black Diamond Therapeutics is a clinical-stage precision oncology medicine company focused on the development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. Black Diamond leverages a deep understanding of cancer genetics and onco-protein structure and function, to discover and develop innovative MasterKey therapies. The Company’s MasterKey therapies are designed to overcome resistance, minimize on-target, wild-type mediated toxicities, and be brain penetrant to address significant unmet medical needs of patients with genetically defined cancers. The Company is advancing a robust pipeline with lead clinical-stage program BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive non-small cell lung cancer (NSCLC) and in glioblastoma multiforme (GBM), and BDTX-4933, a program targeting RAF MasterKey mutations in solid tumors, as well as discovery-stage research programs. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data and validate MasterKey mutations.


Julie Seidel, Stern Investor Relations
(212) 362-1200

Record changed: 2023-01-08


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Black Diamond Therapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Biotech Showcase 2024 San Francisco 650x300px

» top